Clinical Trial Update: Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Disitamab Vedotin with Lenvatinib and PD-1 inhibitors for HER2-positive advanced biliary tract cancer; the study is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Lenvatinib (lenvatinib)
• PD-1 inhibitors

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Biliary Tract Cancer, Disitamab Vedotin | Phase 2 | Status: NOT_YET_RECRUITING